551. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any comparative assessment of the timeframe from marketing authorisation to reimbursement decision for GLP-1 receptor agonists in Ireland relative to other EU Member States; whether she considers the current pharmacoeconomic assessment and negotiation timeline proportionate to the scale of the public health burden posed by obesity and type 2 diabetes; and if she will make a statement on the matter. [15881/26]

Summary

551. Deputy Ken O'Flynn asked the Minister for Health whether her Department has undertaken any comparative assessment of the timeframe from marketing authorisation to reimbursement decision for GLP-1 receptor agonists in Ireland relative to other EU Member States; whether she considers the current pharmacoeconomic assessment and negotiation timeline proportionate to the scale of the public health burden posed by obesity and type 2 diabetes; and if she will make a statement on the matter. [15881/26]

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

1 official file

• Medicinal Products

  xml · EN · 26 February 2026

  ViewDownloadOpen at official source

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.